191 related articles for article (PubMed ID: 37354675)
21. MORPHEAFORM BCC OF ALA NASI: A SUCCESSFUL DERMATOSURGICAL APPROACH BY TRANSPOSITION FLAP FROM THE ADJACENT AREA. CONTAMINATION OF VENLAFAXINE, BISOPROLOL AND OLANZAPINE WITH NITROSAMINES/NDSRIS: THE MOST LIKELY CAUSE OF SKIN CANCER DEVELOPMENT AND PROGRESSION.
Tchernev G; Lozev I; Ivanov L
Georgian Med News; 2023 Sep; (342):26-29. PubMed ID: 37991952
[TBL] [Abstract][Full Text] [Related]
22. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
23. MULTIPLE KERATINOCYTIC CANCERS AFTER ENALAPRIL/LOSARTAN INTAKE: POTENTIAL LINKS TO DRUG MEDIATED NITROSOGENESIS/CARCINOGENESIS: MELOLABIAL ADVANCED FLAP AND UNDERMINING SURGERY AS OPTIMAL THERAPEUTIC APPROACH.
Tchernev G
Georgian Med News; 2023 Nov; (344):196-199. PubMed ID: 38236123
[TBL] [Abstract][Full Text] [Related]
24. Nitrosamine Contamination in Pharmaceuticals: Threat, Impact, and Control.
Tuesuwan B; Vongsutilers V
J Pharm Sci; 2021 Sep; 110(9):3118-3128. PubMed ID: 33989680
[TBL] [Abstract][Full Text] [Related]
25. N-nitrosamines in the southern Swedish rubber industries - exposure, health effects, and immunologic markers.
Jönsson LS; Lindh CH; Bergendorf U; Axmon A; Littorin M; Jönsson BA
Scand J Work Environ Health; 2009 May; 35(3):203-11. PubMed ID: 19404559
[TBL] [Abstract][Full Text] [Related]
26. Telmisartan (and/or nitrosamine) - induced occult melanoma: first reported case in world literature.
Tchernev G; Bitolska A; Patterson JW
Expert Rev Clin Pharmacol; 2021 Sep; 14(9):1075-1080. PubMed ID: 34085580
[No Abstract] [Full Text] [Related]
27. Nitrosamine Impurities in Pharmaceuticals: An Empirical Review of their Detection, Mechanisms, and Regulatory Approaches.
Bhirud D; Agrawal G; Shah H; Patel A; Palkar MB; Bhattacharya S; Prajapati BG
Curr Top Med Chem; 2024; 24(6):503-522. PubMed ID: 38321910
[TBL] [Abstract][Full Text] [Related]
28. KARAPANDZIC FLAP FOR SQUAMOUS CELL CARCINOMA OF THE LOWER LIPP: POTENTIAL ROLE OF NITROSAMINES IN EPROSARTAN AS CANCER TRIGGERING FACTORS.
Tchernev G; Lozev I; Pidakev I; Kordeva S
Georgian Med News; 2023 Jan; (334):83-85. PubMed ID: 36864798
[TBL] [Abstract][Full Text] [Related]
29. Occupational nitrosamine exposure. 1. Rubber and tyre industry.
Spiegelhalder B; Preussmann R
Carcinogenesis; 1983 Sep; 4(9):1147-52. PubMed ID: 6883637
[TBL] [Abstract][Full Text] [Related]
30. Critical Analysis of Drug Product Recalls due to Nitrosamine Impurities.
Bharate SS
J Med Chem; 2021 Mar; 64(6):2923-2936. PubMed ID: 33706513
[TBL] [Abstract][Full Text] [Related]
31. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
32. Lifetime exposure to rubber dusts, fumes and N-nitrosamines and cancer mortality in a cohort of British rubber workers with 49 years follow-up.
Hidajat M; McElvenny DM; Ritchie P; Darnton A; Mueller W; van Tongeren M; Agius RM; Cherrie JW; de Vocht F
Occup Environ Med; 2019 Apr; 76(4):250-258. PubMed ID: 30772818
[TBL] [Abstract][Full Text] [Related]
33. Regulatory Experiences with Root Causes and Risk Factors for Nitrosamine Impurities in Pharmaceuticals.
Horne S; Vera MD; Nagavelli LR; Sayeed VA; Heckman L; Johnson D; Berger D; Yip YY; Krahn CL; Sizukusa LO; Rocha NFM; Bream RN; Ludwig J; Keire DA; Condran G
J Pharm Sci; 2023 May; 112(5):1166-1182. PubMed ID: 36599405
[TBL] [Abstract][Full Text] [Related]
34. The EU Response to the Presence of Nitrosamine Impurities in Medicines.
Ruepp R; Frötschl R; Bream R; Filancia M; Girard T; Spinei A; Weise M; Whomsley R
Front Med (Lausanne); 2021; 8():782536. PubMed ID: 34869504
[TBL] [Abstract][Full Text] [Related]
35. Investigation of Carcinogenic Impurities of N-Nitrosamines in Sartan Pharmaceutical Products Marketed in Brazil: Development and Validation of Method Based on High-Performance Liquid Chromatography-Tandem Mass Spectrometry.
Monteiro MA; de Lima PC; Novotny TS; Santana DS; Lima MED; Dantas ASCL; Ferreira LODS; de Souza MN; Maranho RLDN; Ochs SM
J Pharm Sci; 2023 May; 112(5):1305-1314. PubMed ID: 36657719
[TBL] [Abstract][Full Text] [Related]
36. The contamination of valsartan and other sartans, Part 2: Untargeted screening reveals contamination with amides additionally to known nitrosamine impurities.
Scherf-Clavel O; Kinzig M; Besa A; Schreiber A; Bidmon C; Abdel-Tawab M; Wohlfart J; Sörgel F; Holzgrabe U
J Pharm Biomed Anal; 2019 Aug; 172():278-284. PubMed ID: 31078064
[TBL] [Abstract][Full Text] [Related]
37. Nitrosamine Impurities in Angiotensin Receptor Blockers.
Shephard EA; Nawarskas JJ
Cardiol Rev; 2020; 28(5):262-265. PubMed ID: 32467427
[TBL] [Abstract][Full Text] [Related]
38. Exposure to nitrosamines, carbon black, asbestos, and talc and mortality from stomach, lung, and laryngeal cancer in a cohort of rubber workers.
Straif K; Keil U; Taeger D; Holthenrich D; Sun Y; Bungers M; Weiland SK
Am J Epidemiol; 2000 Aug; 152(4):297-306. PubMed ID: 10968374
[TBL] [Abstract][Full Text] [Related]
39. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
